South Korea
· Delayed Price · Currency is KRW Daewoong Pharmaceutical Statistics
Total Valuation
Daewoong Pharmaceutical has a market cap or net worth of KRW 1.47 trillion. The enterprise value is 2.07 trillion.
| Market Cap | 1.47T |
| Enterprise Value | 2.07T |
Important Dates
The last earnings date was Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Daewoong Pharmaceutical has 11.51 million shares outstanding. The number of shares has increased by 2.68% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 11.51M |
| Shares Change (YoY) | +2.68% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.65% |
| Owned by Institutions (%) | 25.76% |
| Float | 5.35M |
Valuation Ratios
The trailing PE ratio is 16.14 and the forward PE ratio is 14.33. Daewoong Pharmaceutical's PEG ratio is 1.07.
| PE Ratio | 16.14 |
| Forward PE | 14.33 |
| PS Ratio | 1.05 |
| PB Ratio | 1.90 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | 1.07 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.16, with an EV/FCF ratio of -30.26.
| EV / Earnings | 22.79 |
| EV / Sales | 1.48 |
| EV / EBITDA | 10.16 |
| EV / EBIT | 13.17 |
| EV / FCF | -30.26 |
Financial Position
The company has a current ratio of 1.00, with a Debt / Equity ratio of 0.59.
| Current Ratio | 1.00 |
| Quick Ratio | 0.55 |
| Debt / Equity | 0.59 |
| Debt / EBITDA | 3.15 |
| Debt / FCF | -8.07 |
| Interest Coverage | 16.95 |
Financial Efficiency
Return on equity (ROE) is 9.55% and return on invested capital (ROIC) is 5.90%.
| Return on Equity (ROE) | 9.55% |
| Return on Assets (ROA) | 4.56% |
| Return on Capital (ROIC) | 5.90% |
| Revenue Per Employee | 818.16M |
| Profits Per Employee | 53.14M |
| Employee Count | 1,710 |
| Asset Turnover | 0.79 |
| Inventory Turnover | 2.92 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +21.97% in the last 52 weeks. The beta is 0.82, so Daewoong Pharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | 0.82 |
| 52-Week Price Change | +21.97% |
| 50-Day Moving Average | 145,968.00 |
| 200-Day Moving Average | 123,868.50 |
| Relative Strength Index (RSI) | 30.97 |
| Average Volume (20 Days) | 34,482 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Daewoong Pharmaceutical had revenue of KRW 1.40 trillion and earned 90.87 billion in profits. Earnings per share was 7,897.50.
| Revenue | 1.40T |
| Gross Profit | 707.17B |
| Operating Income | 128.56B |
| Pretax Income | 105.00B |
| Net Income | 90.87B |
| EBITDA | 175.08B |
| EBIT | 128.56B |
| Earnings Per Share (EPS) | 7,897.50 |
Balance Sheet
The company has 110.31 billion in cash and 551.97 billion in debt, giving a net cash position of -441.66 billion or -38,384.32 per share.
| Cash & Cash Equivalents | 110.31B |
| Total Debt | 551.97B |
| Net Cash | -441.66B |
| Net Cash Per Share | -38,384.32 |
| Equity (Book Value) | 934.81B |
| Book Value Per Share | 67,149.24 |
| Working Capital | 1.14B |
Cash Flow
In the last 12 months, operating cash flow was 84.73 billion and capital expenditures -153.16 billion, giving a free cash flow of -68.43 billion.
| Operating Cash Flow | 84.73B |
| Capital Expenditures | -153.16B |
| Free Cash Flow | -68.43B |
| FCF Per Share | -5,947.45 |
Margins
Gross margin is 50.55%, with operating and profit margins of 9.19% and 6.50%.
| Gross Margin | 50.55% |
| Operating Margin | 9.19% |
| Pretax Margin | 7.51% |
| Profit Margin | 6.50% |
| EBITDA Margin | 12.51% |
| EBIT Margin | 9.19% |
| FCF Margin | -4.89% |
Dividends & Yields
This stock pays an annual dividend of 600.00, which amounts to a dividend yield of 0.46%.
| Dividend Per Share | 600.00 |
| Dividend Yield | 0.46% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 8.72% |
| Buyback Yield | -2.68% |
| Shareholder Yield | -2.23% |
| Earnings Yield | 6.19% |
| FCF Yield | -4.66% |
Stock Splits
The last stock split was on December 27, 2012. It was a forward split with a ratio of 1.03.
| Last Split Date | Dec 27, 2012 |
| Split Type | Forward |
| Split Ratio | 1.03 |
Scores
Daewoong Pharmaceutical has an Altman Z-Score of 2.23. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.23 |
| Piotroski F-Score | n/a |